Liezl Gambe

SciSparc (NASDAQ:SPRC), a company traditionally focused on cannabinoid-based pharmaceuticals, has officially pivoted into the medical device sector.

MainStreet Bancshares (NASDAQ:MNSB) reported a full recovery in fiscal year 2025, recording net income of $15.6 million following a challenging 2024.

United Therapeutics (NASDAQ:UTHR) has cleared a primary safety hurdle in its ambitious effort to manufacture biological alternatives to human organs, reporting that its bioengineered external liver supported critically ill patients without serious adverse effects.

HBT Financial (NASDAQ:HBT) reported fourth-quarter 2025 results that showcased stable profitability and a robust balance sheet, while charting a path for significant growth in 2026 through a newly announced definitive agreement to acquire CNB Bank Shares.

MannKind (NASDAQ:MNKD) received U.S. Food and Drug Administration approval on Monday for a critical update to the prescribing information for Afrezza, its inhaled mealtime insulin.

Baker Hughes (NASDAQ:BKR) reported fourth-quarter profits that comfortably cleared analyst hurdles, as the company’s strategic shift toward liquefied natural gas (LNG) and industrial energy technology bore fruit against a volatile backdrop for crude prices.

A senior US lawmaker says pro-crypto regulation and economic reforms mark the start of a new national growth phase.

Most institutional investors believe bitcoin is undervalued and say they would hold or buy more despite ongoing market weakness.

Rising US shutdown fears and geopolitical risks triggered a $100bn sell-off across crypto markets.

Monero is under heavy pressure after a sharp sell-off and new restrictions on privacy coins introduced by Indian regulators.